Reata’s Bardoxolone for Alport Syndrome Granted FDA Orphan Drug Status
Bardoxolone methyl, an investigational treatment for kidney damage associated with Alport syndrome, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA), Reata Pharmaceuticals announced. Bardoxolone methyl (bardoxolone) is an oral, once-daily therapy that is being evaluated in the CARDINAL Phase 2/3 clinical trial (NCT03019185) in patients with chronic kidney disease…